Cervical Squamous Cell Carcinoma

Observed

← altered in cohorts of

PIK3CA

83 / 291 cases (29 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

KMT2C

54 / 291 cases (19 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

MUC4

50 / 291 cases (17 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

MUC16

48 / 291 cases (16 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

KMT2D

41 / 291 cases (14 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

FLG

38 / 291 cases (13 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

DMD

37 / 291 cases (13 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

SYNE1

37 / 291 cases (13 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

EP300

35 / 291 cases (12 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

FBXW7

35 / 291 cases (12 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

RYR2

35 / 291 cases (12 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

LRP1B

33 / 291 cases (11 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

USH2A

33 / 291 cases (11 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

ADGRV1

30 / 291 cases (10 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

MUC17

30 / 291 cases (10 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

HUWE1

28 / 291 cases (9.6 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

CSMD1

27 / 291 cases (9.3 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

NEB

26 / 291 cases (8.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

NAV3

25 / 291 cases (8.6 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

AHNAK2

24 / 291 cases (8.2 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

HMCN1

24 / 291 cases (8.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

LRP2

24 / 291 cases (8.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

PCLO

24 / 291 cases (8.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

SYNE2

24 / 291 cases (8.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts

—

Observed

← altered in cohorts of

CREBBP

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

DNAH2

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

DST

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

EYS

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

FAT1

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

MDN1

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

MUC5B

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

TP53

23 / 291 cases (7.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

CSMD3

22 / 291 cases (7.6 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

HYDIN

22 / 291 cases (7.6 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

MKI67

21 / 289 cases (7.3 %) · ssm · cesc_tcga_gdc

—

Observed

← altered in cohorts of

MACF1

21 / 291 cases (7.2 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

PRKDC

21 / 291 cases (7.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

PTEN

21 / 291 cases (7.2 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

CUBN

20 / 289 cases (6.9 %) · ssm · cesc_tcga_gdc

—

Observed

← altered in cohorts of

TENM1

20 / 289 cases (6.9 %) · ssm · cesc_tcga_gdc

—

Observed

← altered in cohorts of

DNAH6

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

FRAS1

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

NIPBL

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018

—

Observed

← altered in cohorts of

NOTCH1

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

OBSCN

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

← altered in cohorts of

UBR4

20 / 291 cases (6.9 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 2 cohorts

—

Observed

Cervical Squamous Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 34show all (up to 200)
→ investigated in trials for	Cisplatinsmall molecule 23 trials (5 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Nimotuzumabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Cervical Squamous Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 34show all (up to 200)

→ investigated in trials for

Cisplatinsmall molecule

23 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

10 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

7 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nimotuzumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Cervical Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 82show all (up to 200)
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07848243Phase 2 · recruiting Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ALIAS · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07147361active not recruiting Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07217171Phase 1 · recruiting A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03074513Phase 2 · active not recruiting Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 82 trials mapped (21 active)	—	—	Human Papillomavirus-Related Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07602842Phase 1/Phase 2 · recruiting A Study of IDP-001 in Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07796672recruiting Feasibility Study of Blood Biomarker Identification in Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02466971Phase 3 · active not recruiting Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06543576Phase 1/Phase 2 · recruiting External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Cervical Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 82show all (up to 200)

→ studied in

NCT07061977Phase 3 · recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT07848243Phase 2 · recruiting

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ALIAS · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT07147361active not recruiting

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT07217171Phase 1 · recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

Human Papillomavirus-Related Cervical Squamous Cell Carcinoma

→ studied in

NCT03074513Phase 2 · active not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT07602842Phase 1/Phase 2 · recruiting

A Study of IDP-001 in Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT07796672recruiting

Feasibility Study of Blood Biomarker Identification in Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT02466971Phase 3 · active not recruiting

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT05827614Phase 1 · terminated

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed

→ studied in

NCT06543576Phase 1/Phase 2 · recruiting

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer · condition mapped CURATED_BROADER · 82 trials mapped (21 active)

—

Observed